Pelthos Therapeutics Inc. (PTHS): CEO Scott Plesha compensation terms

Events in this filing

Item 5.02 as filed

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Amendment to CEO Employment Agreement
On October 30, 2026, Pelthos and Scott Plesha, its Chief Executive
Officer, entered into a Second Amendment to his Executive Employment Agreement dated as of July 1, 2025, as amended (the “Plesha
Amendment”). The Plesha Amendment expands Mr. Plesha’s severance benefits by providing for a prorated annual bonus based on
actual performance, for the year in which Mr. Plesha’s employment terminates.
The foregoing description is qualified in its entirety by reference
to the full text of the agreement, which is filed as Exhibit 10.9 to this Current Report on Form 8-K and incorporated herein by reference.
On October 28, 2026, the Compensation Committee of the Board approved
an increase to Mr. Plesha’s annual base salary from $500,000 to $550,000 and approved an increase to his target annual bonus opportunity
from 50% of base salary to 60% of base salary.